Aiming at the 20 billion high imitation "no man's land", the layout of domestic pharmaceutical companies accelerated

Pharmaceutical Network Market Analysis: With the acceleration of industrialization and the increasing aging phenomenon, respiratory diseases have become a common disease in the worldAccording to a recent survey by the China Lung Health Research and Asthma Alliance Epidemiological Survey published in The Lancet in 2019, nearly 50 million asthma patients in China have a high incidence rate of 8.2% for people over 40 years of age, and is growing at a rate of 4% per year, with only 28.8% of patients being diagnosed and only 15.6% under control.
Respiratory diseases have become the focus of national attentionGlobal respiratory disease synopsis is mainly a chemical-based inhalation agent, which can reach a higher concentration in the respiratory tract, perform faster and have less adverse reactions than systemic administrationData show that in 2020 China's sales of inhaled agents is expected to be close to 20 billion yuan (incomplete statistics), 2013-2019 compound growth rate of 20%, the potential market is expected to reach 60 billion yuan.
However, the technical barriers to the imitation of respiratory inhalation preparations are high, drug particle size, inhalation devices have a greater impact on the efficacy of drugs, making the domestic inhalation preparations market long-term monopoly of imported varietiesData show that in 2018, China's inhaled preparations market 80% occupied by foreign companies, of which nearly 70% of the market by AstraZeneca, GlaxoSmithKline, Bollinger Ingham three multinational pharmaceutical companies occupy, can compete with the domestic enterprises and products less.
Aimated at the blue sea of the market, in recent years, domestic enterprises in inhalation agents technical barriers have also made a breakthrough, there are now more and more enterprises began to lay out, the industry competition pattern is good.
Among them, the health yuan is expected to become the domestic inhalation preparation leaderIn recent years, the health meta-in-depth layout inhalation preparations, 2019 has been inhaled with compound isopropyl tomhate solution, hydrochloric acid zosarbutamine atomized inhalation solution two atomized inhaling agents cash, followed by a number of products such as budinide suspension, sametroltitikatazole dry powder in the market approval, including heavy-duty varieties Budinide inhalation mixed suspension is expected to be listed in June this year, is expected to become the future of nearly 2 billion yuanIn addition, it is expected that by 2025, the health yuan breathing sector product revenue will exceed 5 billion yuan, net profit is expected to exceed 1.2 billion yuan, the future of the business sector will be comparable to the company's total profit volume.
In addition to the health yuan, Zhengda Sunny, Hengrui Pharmaceuticals, Changfeng Pharmaceuticals and other enterprises have also begun to step into the inhalation preparations of high imitation "no man's land."
On February 26 this year, positive day-light inhalation with budined mixed suspension officially obtained the State Drug Administration's drug registration approval for the market, clinically available for glucocorticoid dependence or treatment of bronchial asthmaThe successful listing of the boutined mixed suspension will break the market pattern of the variety that has long been monopolized by the international pharmaceutical giants, and quickly break through the "card neck" link to meet the urgent needs of patients with chronic respiratory diseases in China.
On November 8, 2019, Hengrui Pharmaceuticals announced that its Malay acid Datro Inhaled Powder Mist Has Been Awarded a Clinical Trial Notice and will soon conduct a clinical trial of a new type of long-acting beta-2-receptor agonist intended for the maintenance of adult chronic obstructive pulmonary disease (COPD) patients.
Changfeng Pharmaceuticals' research product line covers a full range of respiratory products, involving asthma, chronic obstructive pulmonary disease, allergic rhinitis and other clinically needed treatment areas At the same time, Changfeng Pharmaceuticals has built a platform for the development and production of four major inhalation agents: quantitative inhalation aerosols, dry powder inhalers, atomized inhalers and nasal sprays.
The industry believes that with the continuous promotion of health insurance policy, as well as a series of policies to support domestic drug innovation and the localization of medical devices, it is hoped that domestic inhalation preparation enterprises research and development, further accelerate the domestic substitution of inhaled preparations, break the monopoly pattern of the original research drug of multinational enterprises.